Skip to main content

Table 2 Summary of results in patients on VSL#3®

From: A randomised placebo controlled trial of VSL#3® probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease

Measurements

Mean pre-VSL#3®

Mean post-VSL#3®

p value

Systolic BP (mmHg)

133 ± 13

130 ± 11

0.53

Diastolic BP (mmHg)

82 ± 8

80 ± 7

0.42

Total cholesterol (mmol/l)

4.51 ± 1.38

4.42 ± 1.27

0.83

HDL (mmol/l)

1.07 ± 0.26

1.09 ± 0.24

0.79

LDL (mmol/l)

2.58 ± 1.18

2.56 ± 1.02

0.95

Triglycerides (mmol/l)

1.89 ± 0.57

1.91 ± 1.00

0.94

HbA1c (mmol/mol)

54 ± 12

55 ± 12

0.87

Fructosamine (μmol/l)

257 ± 44

263 ± 49

0.67

HOMA-IR

2.2 ± 1.9

2.2 ± 1.5

0.95

∆RI-GTN (%)

28 ± 6

25 ± 8

0.20

∆RI-Salb (%)

9 ± 8

8 ± 4

0.62

sVCAM-1 (ng/ml)

536 ± 305

524 ± 262

0.90

cGMP (pmol/l)

178 ± 57

159 ± 43

0.27

Blood glutathione ratio

22 ± 10

26 ± 13

0.21

TAC [mM Asc (AEAC)]

0.46 ± 0.04

0.47 ± 0.07

0.75

hsCRP (mg/l)

3.0 ± 2.5

3.9 ± 6.1

0.53

ALT (iu/l)

56 ± 31

51 ± 32

0.63

AST (iu/l)

40 ± 16

38 ± 20

0.78

Mode ASQ (C2m)

91 ± 14

95 ± 16

0.57

  1. VSL#3® treated group n = 19; placebo treated group n = 16. Data expressed as mean and standard deviation. Four cGMP values were not measurable (3 from placebo group and 1 from VSL#3® group). HOMA-IR missing 1 value from each treatment group as insulin levels were outside the HOMA calculator range. HbA1c in the placebo group had one missing value. LDL cholesterol had missing data on 1 patient from placebo group and 1 from VSL#3® group as triglycerides were > 4.5 mmol/l which preclude LDL cholesterol calculation. SBP and DBP values were missing after intervention on 1 patient in the placebo group. Nineteen patients had completed ASQ (10 in VSL#3® group and 11 in placebo group). Missing data were excluded from respective analyses